Veloxis Pharmaceuticals announced that LCP-Tacro successfully demonstrated non-inferiority compared to tacrolimus (Prograf®; Astellas Pharma) in its Phase III clinical trial, Study 3002.
The Phase III randomized, double-blind and double-dummy study in 543 de novo kidney transplant recipients, with Prograf as the comparator, met its primary efficacy and primary safety endpoints.
The study was conducted under a Special Protocol Agreement with the FDA and the results are considered pivotal for the planned U.S. regulatory filing expected to occur in the second half of 2013.
"The results observed in this clinical trial suggest that new kidney transplant patients can begin with a regimen of once-daily LCP-Tacro™ rather than twice-daily as required with current tacrolimus products, without compromising efficacy and tolerability," said Dr. Suphamai Bunnapradist, M.D., Professor of Medicine and Director of Kidney Transplant Research at the Ronald Reagan Medical Center and David Geffen School of Medicine at UCLA, California, USA. "This is important because once-daily dosing should be beneficial for kidney transplant patients who are on life-long complex therapy."
LCP-Tacro demonstrated non-inferiority to Prograf in preventing kidney transplant rejection, including in the early post-transplant period
The primary endpoint of the study was a composite endpoint of treatment failure (biopsy-proven acute rejection or BPAR, graft failure, loss to follow up or death) that was evaluated after a 12-month treatment period to demonstrate the non-inferiority of LCP-Tacro compared to Prograf.
The treatment failure rate for LCP-Tacro was 18.3% compared to 19.6% for Prograf, well within the 10% pre-specified non-inferiority margin.
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- Part I: Bee Deaths Mystery Solved? Neonicotinoids (Neonics) May Actually Help Bee Health
- Part II: Bee Deaths And CCD - Flawed Chensheng Lu Harvard Studies Endanger Bees
- Violence, Sex And Taboo: The Original Brothers Grimm Fairy Tales Back In Print
- Volunteer-Based Peer Review: A Success
- Bitcoin And Anonymity: User's Identity Can Be Revealed Much Easier Than Thought
- The BPA Paradox – Too Many Studies?
- Education: Stop New Age Thinking, Chalk And Talk Might Be The Best Way After All
- "As someone who has received NIH funding, I can tell you the answer is magic and pure coincidence..."
- "I never thought of diminutive as having a positive or negative association. I often describe people's..."
- "For the most part, I found your article compelling. It reminded me of the time in graduate school..."
- "Indeed, my little experiment does not prove anything; it is not scalable. Not the $10, not the..."
- "Most students take it to battle tiredness and lack of focus, so they study a lot more on the drug..."
- Endangered hammerhead shark found migrating into unprotected waters
- Female color perception affects evolution of male plumage in birds
- Diagnosing deafness early will help teenagers' reading development
- 'Utter neglect' of rheumatic heart disease revealed by results from global study
- Sweet-smelling breath to help diabetes diagnosis in children